Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular uterine bleeding associated with uterine leiomyoma

Socolov, Demetra; Blidaru, I; Tamba, Bogdan Ionel; Miron, Nora; Boiculese, Lucian; Socolov, Răzvan

doi:10.3109/13625187.2011.614028

Cited by 31 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, in the study by Socolov et al .,[3] 89% of women with fibroids considered LNG IUS as a good treatment.…”

Section: Discussionmentioning

confidence: 74%

“…A study by Socolov et al .,[3] evaluating LNG IUS use in menorrhagia due to fibroids showed that 96% of the patients had achieved oligomenorrhea by 1 year.…”

Section: Discussionmentioning

confidence: 99%

“…It is known to reduce the amount of bleeding by over 90% due to its continuous progestogenic effect on the endometrium. [2] LNG-IUS has also been used in patients having fibroids,[3] adenomyosis[4] and endometriosis. [5] Such usage can reduce the need for hysterectomy, with its morbidity, and mortality.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Are women satisfied when using levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding?

Mansukhani

Unni

Dua³

et al. 2013

J Mid-life Health

View full text Add to dashboard Cite

Aim:To determine the efficacy of levonorgestrel intrauterine system (LNG IUS) in treatment of abnormal uterine bleeding (AUB) in women over 35 years and to determine satisfaction of users of LNG IUS in case of AUB.Materials and Methods:This was a multicentric, retrospective, and observational study. Case records of patients with AUB from the hospitals in Pune, Delhi, and Gurgaon for the last 6 years were examined. Records of 80 women who had an LNG IUS inserted were included. The chief complaints and their duration were recorded. Investigation results, histopathology reports, and date of LNG IUS insertion were noted. The incidence of spotting, heavy menstrual bleeding, pain, expulsion, and amenorrhea were recorded at 3, 6, 12, and 18 months following treatment. Following this a telephonic interview was conducted to determine the efficacy of LNG IUS in treating the symptoms. Patients’ satisfaction in percentage was also noted and they were asked if they would recommend the LNG IUS to other women.Results:The mean age of women was 42.3 years. 77.5% of the women had menorrhagia as the chief complaint, and the mean duration was 12 months. Fibroids and adenomyosis were the most common pathology, present in 21.3% and 20% of the patients respectively. At 3 months, spotting seemed to be the predominant symptom (59.4%) and only 15% women had heavy bleeding. 49.3% of women were asymptomatic at 6 months. 27.5% had amenorrhea by the end of 18 months. 14 women in whom the device was expelled or removed due to persistent symptoms, underwent hysterectomy at various stages during the study period. Overall patient satisfaction was high at about 80%. Furthermore, 73.8% patients agreed to recommend it to other women.Conclusion:LNG IUS seems to be a viable and effective treatment option for AUB in women after 35 years. There is a high rate of patient satisfaction in appropriately selected patients.

show abstract

“…Similarly, in the study by Socolov et al .,[3] 89% of women with fibroids considered LNG IUS as a good treatment.…”

Section: Discussionmentioning

confidence: 74%

“…A study by Socolov et al .,[3] evaluating LNG IUS use in menorrhagia due to fibroids showed that 96% of the patients had achieved oligomenorrhea by 1 year.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Are women satisfied when using levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding?

Mansukhani

Unni

Dua³

et al. 2013

J Mid-life Health

View full text Add to dashboard Cite

show abstract

“…Additionally, hemoglobin levels increased by 2 g/dL in the LNG-IUD group compared to 0.1 g/dL in the COC group. Another prospective study of 102 women with leiomyomas and AUB-L administered the LNG-IUD to all subjects [ 14 ]. The primary outcome, menstrual bleeding, decreased signifi cantly over the year of the study, with 89 % of participants being satisfi ed with the LNG-IUD.…”

Section: Abnormal Uterine Bleedingleiomyomata (Aub-l)mentioning

confidence: 99%

Using Contraceptives for Gynecologic Conditions

Kattan

Burkman

2014

Contraception for the Medically Challenging Patient

View full text Add to dashboard Cite

“…Women, therefore, need some therapy to tide over this difficult time. Levonorgestrel intrauterine system (LNG IUS) is a nonsurgical, long acting, alternative to the traditional medical and surgical treatments that is one such feasible option in these women [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Levonorgestrel Releasing Intrauterine System for the Treatment of Adenomyosis in Perimenopausal Women

Guo¹

2015

Gynecol Obstet (Sunnyvale)

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena) in the treatment of menorrhagia, dysmenorrhea and poor quality of life caused by adenomyosis in perimenopausal women. Patients and methods:Ninety-six women with menorrhagia, dysmenorrhea and poor quality of life with adenomyosis in perimenopausal women were included and were invited to complete a SF-36 Health Survey. Exclude cervical and endometrial lesions through underwent a Pap smear, transvaginal sonography and endometrial biopsy. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC), and dysmenorrhea intensity was assessed by a visual analogue scale (VAS). They were followed up after 1 month, 3 months, 6 months, 12 months, and after 18 months. The participations are asked to complete the short form 36 (SF-36) health survey questionnaires. Results:The menstrual blood size was (60.287 ± 21.832) (41.186 ± 16.153), (30.988 ± 15.670), (19.238 ± 13.649), (16 ± 11.464) after treatment 1, 3, 6, 12, and after 18 months, respectively, which reduced significantly compare with before treatment (88.691 ± 33.775, P< 0.05). The VAS of dysmenorrheal dropped continuously and significantly from the baseline score of (74.968 ± 15.889) to (38.797 ± 16.781), (24.857 ± 16.595), (15.840 ± 14.305), (10.784 ± 13.593) and (8.196 ± 12.919), respectively, after treatment 1, 3, 6, 12, and after 18 months of the LNG-IUS insertion (P < 0.05). The results of SF-36 Health Survey shown the quality of life was significantly improved. Conclusion:These data suggest that LNG-IUS is a safe and effective option for reduces menorrhagia, relieve dysmenorrhea and improve the quality of life in patients with adenomyosis from perimenopausal women.

show abstract

Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular uterine bleeding associated with uterine leiomyoma

Abstract: The LNG-IUS is effective in controlling heavy menorrhagia and/or frequent irregular uterine bleeding related to the presence of myomas, but has no significant effect on the size of the tumours.

Cited by 31 publications

References 23 publications

Are women satisfied when using levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding?

Are women satisfied when using levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding?

Using Contraceptives for Gynecologic Conditions

Clinical Efficacy of Levonorgestrel Releasing Intrauterine System for the Treatment of Adenomyosis in Perimenopausal Women

Contact Info

Product

Resources

About